DexCom, Inc. vs Teucrium Wheat Fund — how do they compare? DexCom, Inc. trades at $90.54 (market cap $33.79B), while Teucrium Wheat Fund trades at $24.39. The key difference: DexCom, Inc. is trading nearer its 52-week high, Teucrium Wheat Fund nearer its low. Which is the better fit depends on your goals.
| DXCM | WEAT | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $89.53 | $26.00 |
52-Week Low | $54.84 | $19.88 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
WEAT, the Teucrium Wheat Fund, trades at $24.42, up 1.71% today, with a bullish technical signal from moving averages. Recent news highlights a 9.9% monthly gain, driven by wheat price increases and USDA production cuts. The ETF's performance is closely tied to agricultural commodity markets and inflation trends.
Outlook remains influenced by supply dynamics and inflation; opportunities exist from sustained commodity strength, but risks include weather volatility and economic shifts that could pressure wheat prices and ETF returns.
Trailing returns across standard periods
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →